University of Wisconsin School of Medicine and Public Health
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD)
The PI of this project was:
This project was funded by: Merck
The term of this project was: April 2015 to January 2018
The number of subjects scanned during this project was: 20